Skip to main content
Premium Trial:

Request an Annual Quote

Pressure Biosciences Q3 Revenues Fall 8 Percent

NEW YORK (GenomeWeb) – Pressure Biosciences reported yesterday a nearly 8 percent drop in third quarter revenues as increased instrument sales failed to offset a decline in grant revenues.

For the three-month period ended Sept. 30, Pressure's revenues fell to $535,334 from $580,334 in the same quarter last year. Instrument sales were up nearly 13 percent to $383,789 from $340,084 a year ago, but the increase was  more than offset by a decline in grant revenues to $34,385 from $98,882.

Pressure's Q3 net loss grew to $945,207, or $.03 per share, from a year-ago net loss of $657,928, or $.03 per share. Shares used to calculate the loss per share in the third quarter 2016 were approximately 29.4 million, compared with roughly 20.7 million in the same quarter last year.

R&D spending in the quarter fell to $268,317 from $355,574. The year-ago figure includes the cost of research performed by a customer on Pressure's behalf. SG&A costs, meanwhile, shrank 35 percent to $455,930 from $705,684.

At the end of the third quarter, Pressure had cash and cash equivalents totaling $41,939.

Following the recent achievement of several milestones, including the launch of the next-generation Barocycler 2320Extreme mass spectrometry protein sample prep instrument, Pressure is now focused on expanding and enhancing its "current financial, operational, and technical capabilities, and … [finding] additional ways to help ensure that our progress is seen and understood by the worldwide financial and investor communities," Pressure President and CEO Richard Schumacher said in a statement. 

Doing so, he added, "may include, among other things, additions to staff, independent agents, distributors, and consultants focused primarily in sales and marketing."

The Scan

J&J Booster Support

A US Food and Drug Administration advisory panel has voted to support a booster dose of Johnson & Johnson's SARS-CoV-2 vaccine, according to the Los Angeles Times.

To Keep the Cases Moving

The president of the UK Royal College of Pathologists tells the Financial Times that more investment is needed to tackle a backlog of cases.

NAS Expels Archaeologist

Science reports Luis Jaime Castillo Butters' expulsion is the first of an international member from the US National Academy of Sciences.

PLOS Papers on Angelman Syndrome-Like Cases, Salmonella Paratyphi A, SARS-CoV-2 in Brazil

In PLOS this week: exome sequencing analysis of Angelman syndrome-like cases, genetic epidemiology of Salmonella Paratyphi A, and more.